Vancouver-based psychedelic drugs company Clearmind Medicine has filed a patent application with the International Patent Cooperation Treaty about proprietary combinations of ketamine and N-acyl ethanolamines.
The filing is part of a broader collaboration with clinical-stage pharmaceutical company SciSparc to develop novel psychedelic-derived therapeutics for under-treated mental health conditions.
Analyst QuickTake: Since the collaboration in March 2022, Clearmind Medicine and SciSparc have submitted 13 different patent applications. The latest filing reinforces their commitment to pioneering effective and safer treatments.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.